Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
Sham Mailankody(Memorial Sloan Kettering Cancer Center), Shaji Kumar(Mayo Clinic), Myo Htut(City Of Hope National Medical Center), Saurabh Chhabra(Medical College of Wisconsin), Erin E. Karski(Allogene Therapeutics (United States)), Myles Dillon(Allogene Therapeutics (United States)), Olalekan O. Oluwole(Vanderbilt University), Arun Balakumaran(Allogene Therapeutics (United States)), Wendy Ying(Allogene Therapeutics (United States)), Wade Lovelace(Allogene Therapeutics (United States)), Eric Butz(Allogene Therapeutics (United States)), Michaela Liedtke(Cancer Institute (WIA)), Shahbaz A. Malik(University of Nebraska at Omaha), Rajneesh Nath(The University of Texas MD Anderson Cancer Center), Jeffrey Matous(Colorado Blood Cancer Institute), Faiz Anwer(Cleveland Clinic), José Carlos Cruz(CHRISTUS Transplant Institute), Surbhi Sidana(Palo Alto University)
Cited by 239
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
|Journal of Clinical Oncology|2012|965
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782